Date: 2016-12-05
Type of information: Nomination
Compound:
Company: ViiV Healthcare (UK - USA)
Therapeutic area: Infectious diseases
Type agreement: nomination - resignation
Action mechanism:
Disease:
Details:
- • On December 5, 2016, ViiV Healthcare announced that after seven years as CEO, Dr Dominique Limet will step down at the end of March 2017. Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will succeed him, and will take up the CEO Designate role on 1 January 2017.
- Dominique Limet started his career as a General Practitioner in France. He joined GSK in 1996 from Ciba Geigy, where he held various marketing and management positions. In 2000, Dominique was appointed General Manager of GSK France. He then became SVP, Southern & Eastern Europe Area Director and then Head of GSK Personalised Medicine Strategy.
- Deborah Waterhouse joined GSK in 1996 and is currently SVP Primary Care in US Pharmaceuticals, prior to which she led the US Vaccines business. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA and a strong track record of performance in both specialty and primary care. She led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and SVP Central and Eastern Europe.
- Cheryl MacDiarmid has been appointed to succeed Deborah as SVP US Pharmaceuticals Primary Care. Cheryl has served as VP US Primary Care Sales since early 2015 and been instrumental in shaping the US Primary Care strategy, delivering performance and renewing the culture of patient and customer focus. She brings 20 years of deep experience in establishing key brands and building businesses in the US and Canada, and is known for creating and leading engaged, high-performing teams.
Financial terms:
Latest news:
Is general: Yes
